Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2012

View Archived Issues

Merck & Co.'s M-676 enhances activity of beta-lactam antibiotics

Serum amyloid A shows potential as a novel biomarker

Actelion presented results of cadazolid preclinical and phase I studies

Piramal Imaging presents new imaging agents for Alzheimer's disease

Merck & Co. discloses novel CGRP receptor antagonists

Scientists at Chemilia divulge novel anticancer agents

A-1264087, a novel calcium channel blocker with antinociceptive activity

Italian group prepares new series of tyrosine kinase inhibitors

New PI3Kdelta inhibitors synthesized at Roche

Nabi Biopharmaceuticals reports results from phase II NicVAX vaccine study

Phase II Adcetris monotherapy trial initiated in untreated Hodgkin's lymphoma

Pharmascience patents novel HSP 90 inhibitors

CytoDyn acquires antibody inhibiting HIV entry

Phase III axitinib study fails to meet primary endpoint

First-in-human study of ODM-201 shows good tolerability and anticancer activity in mCRPC

Preclinical pharmacokinetic properties disclosed for G-773

Wilex reports data from phase III ARISER study

FDA advisory committee recommends approval of lomitapide for HoFH

Novavax discloses topline results from two phase I trials of avian influenza vaccine

Prolor Biotech reports preclinical RPeg toxicology data

FDA grants first approval to ocriplasmin

FDA approves Kamada's inhaled alpha-1 antitrypsin IND

NPT-001 shows encouraging effects in preclinical model of Parkinson's disease

Preliminary phase II findings for MABP-1 in psoriasis

Abbott initiates phase III trial of interferon-free HCV regimen, triggering milestone to Enanta

AbD Serotec licenses HuCAL antibodies to DiaSorin

Chiesi completes phase I trial of inhaled CHF-6001

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...